Sensible Biotechnologies
Oxford, United KingdomFounded 202124+ employeesPrivate
$10.4M raisedSeed· last: grant (Sep 2025)· 4 rounds
Backed by(13 investors)
The future of mRNA therapeutics is hampered by manufacturing challenges and unless solved, its exciting potential may never be realised. Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
